ICON Public Limited Company (NASDAQ:ICLR) is a top pick among cheap healthcare stocks to buy heading into 2026, with BMO Capital maintaining a ‘Market Perform’ rating and $175 price target. The analyst call discussed senior executive changes and trends surrounding cancellations in the company.

The analyst also evaluated ICON’s functional work dynamics and plans to invest in automation and AI. Discussions centered on pass-through revenue impact on margins in the future. BMO Capital started coverage on ICLR on November 13, noting cancellations to remain elevated in upcoming quarters.

With a ‘Buy’ rating from most analysts and a median price target of $213.50, ICON Public Limited Company (NASDAQ:ICLR) has a potential upside of nearly 15%. Established in 1989, ICLR is an Ireland-based clinical research organization offering outsourced development and commercialization services.

While ICLR shows promise as an investment, consider AI stocks with greater upside potential and less downside risk. For a detailed report on the best short-term AI stock, check out the link provided. Disclosure: None.

Read more at Yahoo Finance: BMO Capital Maintains Outlook On ICON Public Limited Company (ICLR) After Management Call